Search This Blog

Monday, March 2, 2026

Sionna non-GAAP EPS $-0.46 (+86% YoY), revenue $0

 

Sionna Therapeutics posts Q4 2025 results with non-GAAP EPS $-0.46 (+86% YoY), revenue $0, beats estimates, highlights $310.3M cash funding operations into 2028

  • Company also posted full-year 2025 financial results alongside the Q4 2025 release.
  • Reaffirmed mid-2026 topline data timelines for its key cystic fibrosis clinical trials.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)